Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bevacizumab Biosimilar Nears Market As Amgen Files First At FDA

Executive Summary

What is believed to be the first biosimilar version of Roche's Avastin to be filed with the US FDA has come from Amgen working in collaboration with Allergan, with the two companies heading a dozen-strong group of companies racing to develop versions of the monoclonal antibody.

Advertisement

Related Content

Amgen/Allergan Target Lucrative Avastin Market With Another Biosimilar Filing
Stockwatch: The Post-Truth Biopharma Rally
Keeping Track: FDA Approves First Rx DHEA, Receives Applications For Midostaurin, Gesulkumab, Biosimilar Avastin
Roche's Post-Avastin Strategy Stumbles As Vanucizumab Fails In Phase II
Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond
Defender Or Opponent? Amgen Straddles The Biosimilar Line

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097687

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel